Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment-Reference-Cited by-同舟云学术

Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment

Published:2021-09-13 Issue: Volume: Page:
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Sumpton Daniel¹²³^ORCID,Kelly Ayano²⁴⁵^ORCID,Craig Jonathan C.⁶,Hassett Geraldine⁴⁵⁷,Kane Barry³^ORCID,Oliffe Michael⁴⁷,Tong Allison¹²,Howell Martin¹²

Affiliation:

1. Sydney School of Public Health University of Sydney Sydney 2006

2. Centre for Kidney Research The Children's Hospital at Westmead Westmead 2145

3. Department of Rheumatology Concord Repatriation and General Hospital Concord 2170

4. Department of Rheumatology Liverpool Hospital and Ingham Institute for Applied Medical Research Liverpool 2170

5. Western Sydney Clinical School University of New South Wales Medicine Sydney 2052

6. College of Medicine and Public Health Flinders University Adelaide 5042

7. School of Medicine Western Sydney University Campbelltown 2560

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.24782

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network;Rheumatology International;2024-08-13

2. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database;Frontiers in Immunology;2024-05-23

3. Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe;The Patient - Patient-Centered Outcomes Research;2023-01-11

4. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit;Clinical Drug Investigation;2022-06